Semaglutide: nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: a disproportionality analysis
This phosphorylation acts like a molecular off switch
For example, when someone doesnt have type 2 diabetes, their healthcare provider prescribes Ozempic as off-label use for weight management. 18 Dispelling the Myths Now While not new, GLP-1 drugs have been approved by FDA only in the last decade to treat obesity
The difference lies in how effectively and persistently each medication activates GLP-1 receptors
Cost Comparison Table Insurance Coverage Saxenda: FDA-approved for weight loss Some plans cover with prior authorization May have quantity limits or step therapy requirements Ozempic: FDA-approved for diabetes, not weight loss Often covered for diabetic patients Rarely covered for weight loss alone Wegovy: FDA-approved for weight loss Coverage varies widely Many plans exclude weight loss medications Cost Efficiency When comparing cost per outcome: Saxenda: At $200/month for 12 months ($2,400) producing 15-18 pounds loss = ~$133-160 per pound lost Semaglutide: At $199/month for 12 months ($2,388) producing 30-35 pounds loss = ~$68-80 per pound lost Semaglutide provides substantially better value when considering weight loss achieved per dollar spent
Farmacia Guadalajara is another major chain with widespread coverage
